Skip to main content

Table 2 Cell surface phenotype of immature and mature dendritic cells from breast cancer patients

From: Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency

Donors/patients Immature DCs/mature DCs
Healthy donors
   Donor M13 N14 015
   CD40 79/95 80/97 84/96
   CD80 0.1/90 1/97 18/91
   CD83 2/52 8/48 19/40
   CD86 85/98 68/98 57/97
   IL-10 43/46 47/214 89/112
   IL-12 5/400 7/29 5/182
Patients with breast cancer
   Patient S219 S221 S222
   CD40 91/93 42/86 77/86
   CD80 3/84 4/76 4.5/72
   CD83 8/17 14/66 14/72
   CD86 87/89 25/86 68/89
   IL-10 46/0 57/132 30/63
   IL-12 bdl/2154 bdl/1280 bdl/1261
  1. Data are expressed as the percentage of HLA-DR+ cells expressing CD40, CD80, CD83 and CD86, and IL-10 and IL-12 production by dendritic cells (DCs) before and after maturation with cocktail C: Ribomunyl®/Imukin®. Data are individual values from patients S219, S221 and S222. Controls are from three different donors (M13, N14, O15). bdl, below the detection limit; DC, dendritic cell.
\